September 25th – 27th, 2017 – San Jose, California
The MedTech Conference is your opportunity to connect with thousands of medical technology professionals this September. Join us in San Jose for business development, innovative technology, and networking with policymakers, business executives and industry leaders.
Calling all medical device innovators! This year’s symposium will host the National Capital Consortium for Pediatric Device Innovation (NCC-PDI) competition. Up to six innovations will be awarded up to $50,000 each during the “Make Your Medical Device Pitch for Kids!” competition.
At the John’s Hopkins Kimmel Cancer Center, researchers have been working for years to figure out how prostate cancer cells are able to move from one infected organ and spread to other parts of the body.
“Because we know that’s the type of cancer that eventually will kill a man with prostate cancer,” said Johns Hopkins Associate Professor of Oncology and Pathology. Dr. Srinivasan Yegnasubramanian.
AstraZeneca and its global biologics research and development arm MedImmune, has appointed Dr Geoffrey Kim and Dr Jean-Charles Soria, respectively. Kim and his team will focus on the development of the company’s late-stage immuno-oncology combinations programme, aiming to develop combination regimens that will deliver innovative medicines to patients.
It figures a personalized health accelerator would want to personalize the experience for its companies.
When Virginia health system Inova Health closed on the 117-acre former Exxon-Mobil campus in Fairfax back in 2015, it was clear there was plenty of space to do something bold. (It was called the real estate deal of the year.) And from the start personalized medicine was going to be the focus.
The company alleges the U.S. Food and Drug Administration isn’t honoring a drug designation program Congress passed in 1983.
You are invited to travel with County Executive Ike Leggett, MCEDC, other county officials and select area business leaders on an exclusive Business Development trip to South Korea and China, October 20-29, 2017. Our delegation will visit some of the most forward-thinking technology hubs and global commerce destinations of East Asia including Seoul, Daejeon, Xi’an and Shanghai.
Between now and 2020, we can expect to see a wave of innovation in pharma. But how will the coming drug launches fare in today’s challenging market? Consider these facts: the number of drugs per indication has risen by 37 percent since 2006, while the top company in an indication still commands at least half of the market. At the same time, restrictions to market access are rising in Europe, the United States, and emerging economies as advances in analytics and multichannel engagement open new opportunities to differentiate products.
Gilead Sciences, under intense investor pressure to do a significant M&A deal, may have found a target it likes. It is said to be evaluating United Therapeutics, although it finds itself in competition with GlaxoSmithKline and perhaps others.
The Evening Standard, citing unnamed sources, said that Gilead Sciences is considered the most likely candidate to win a bid for United Therapeutics. But the newspaper also said that GSK has Citi and Lazard helping it assess the United, a company founded in 1996 on a pulmonary arterial hypertension (PAH) drug that had been discarded by GSK.
WellDoc® and the American Association of Diabetes Educators (AADE) announce the collaborative launch of “The Diabetes Digital Health Learning Network” at the AADE17 conference. The goal of this Learning Network is to assist diabetes educators in gaining next-generation skills in using digital health therapeutics to improve clinical care and outcomes cost-effectively. “As a digital health leader, WellDoc is proud to launch ‘The Diabetes Digital Health Learning Network’ in collaboration with AADE to support its members who are on the front lines of diabetes care and management,” said WellDoc President and CEO Kevin McRaith. “This is a natural progression of our already-established partnership with AADE that began with our collaboration to incorporate The AADE Diabetes Education Curriculum into our FDA-cleared digital therapeutic platform, BlueStar®.”
